Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is useful in predicting responses to angiogenic therapy of malignant tumors.
Purpose
To observe the dynamics of DCE-MRI parameters in evaluating early effects of antiangiogenic therapy in a C6 glioma rat model.
Material and Methods
The Bevacizumab or vehicle treatment was started from the 14th day after glioma model was established. The treated and control groups (n = 13 per group) underwent DCE-MRI scans on days 0, 1, 3, 5, and 7 after treatment. Tumor volume was calculated according to T2-weighted images. Hematoxylin and eosin, microvessel density (MVD), and proliferating cell nuclear antigen (PCNA) examination were performed on day 7. The MRI parameters between the two groups were compared and correlations with immunohistochemical scores were analyzed.
Results
The average tumor volume of treated group was significantly lower than that of control group on day 7 (81.764 ± 1.043 vs. 103.634 ± 3.868 mm3, P =0.002). Ktrans and Kep decreased in the treated group while they increased in the control group. The differences were observed on day 5 (Ktrans: 0.045 ± 0.018 vs. 0.093 ± 0.014 min−1, P <0.001; Kep: 0.062 ± 0.018 vs. 0.134 ± 0.047 min−1, P =0.005) and day 7 (Ktrans: 0.032 ± 0.010 vs. 0.115 ± 0.025 min−1, P <0.001; Kep: 0.045 ± 0.016 vs. 0.144 ± 0.042 min−1, P <0.001). The difference of Ve was observed on day 5 (0.847 ± 0.248 vs. 0.397 ± 0.151, P =0.009) and 7 (0.920 ± 0.154 vs. 0.364 ± 0.105, P =0.006). Ktrans and Kep showed positive correlations with MVD and Ve showed negative correlation with PCNA.
Conclusion
DCE-MRI can assess the changes of early effects of anti-angiogenic therapy in preclinical practice.
StuppRMasonWPvan den BentMJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med2005;
352:987–996.
2.
FolkmanJ.Role of angiogenesis in tumor growth and metastasis.Semin Oncol2002;
29:15–18.
3.
KimMMUmemuraYLeungD.Bevacizumab and glioblastoma: Past, present, and future directions.Cancer J2018;
24:180–186.
4.
TamuraRTanakaTMiyakeK, et al.
Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.Brain Tumor Pathol2017;
34:62–77.
5.
CastroBAAghiMK.Bevacizumab for glioblastoma: current indications, surgical implications, and future directions.Neurosurg Focus2014;
37:E9.
6.
LyonKAHuangJH.Bevacizumab as an adjuvant therapy for glioblastoma in elderly patients: the facts.Transl Cancer Res2018;
7(Suppl 7):S802–S805.
7.
TamuraRTanakaTMiyakeK, et al.
Histopathological investigation of glioblastomas resected under bevacizumab treatment.Oncotarget2016;
7:52423–52435.
8.
PopeWBLaiANghiemphuP, et al.
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.Neurology2006;
66:1258–1260.
9.
VarallyayCGMuldoonLLGahramanovS, et al.
Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model.J Cereb Blood Flow Metab2009;
29:853–860.
10.
BonekampDDeikeKWiestlerB, et al.
Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: comparison of intraindividually matched T1- and T2 (*)-based bolus techniques.J Magn Reson Imaging2015;
42:87–96.
11.
GulliksrudKHomplandTGalappathiK, et al.
Assessment of tumor hypoxia and interstitial fluid pressure by gadomelitol-based dynamic contrast-enhanced magnetic resonance imaging.Radiother Oncol2011;
101:217–222.
12.
EgelandTAGaustadJVVestvikIK, et al.
Assessment of fraction of radiobiologically hypoxic cells in human melanoma xenografts by dynamic contrast-enhanced MRI.Magn Reson Med2006;
55:874–882.
13.
JainKKSahooPTyagiR, et al.
Prospective glioma grading using single-dose dynamic contrast-enhanced perfusion MRI.Clin Radiol2015;
70:1128–1135.
14.
SaraswathySCrawfordFWLambornKR, et al.
Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.J Neuro-Oncol2009;
91:69–81.
15.
QianWXuXQHuH, et al.
Dynamic contrast-enhanced MRI in orbital lymphoproliferative disorders: Effects of region of interest selection methods on time efficiency, measurement reproducibility, and diagnosticability.J Magn Reson Imaging2018;
47:1298–1305.
16.
von BaumgartenLBruckerDTirniceruA, et al.
Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells.Clin Cancer Res2011;
17:6192–6205.
17.
EgelandTAGulliksrudKGaustadJV, et al.
Dynamic contrast-enhanced-MRI of tumor hypoxia.Magn Reson Med2012;
67:519–530.
18.
ManiniICaponnettoFBartoliniA, et al.
Role of microenvironment in glioma invasion: What we learned from in vitro models. Int J Mol Sci2018;
19:E147.
19.
ChoHAckerstaffECarlinS, et al.
Noninvasive multimodality imaging of tumor microenvironment: Registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia.Neoplasia2009;
11:247–259.
20.
BatchelorTTSorensenAGdi TomasoE, et al.
AZD2171, a Pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.Cancer Cell2007;
11:83–95.
21.
GuoJGlassJOMcCarvilleMB, et al.
Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI.Br J Cancer2015;
113:1282–1288.
22.
KunkelPUlbrichtUBohlenP, et al.
Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res2001;
61:6624–6628.
23.
GuleMKChenYSanoD, et al.
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.Clin Cancer Res2011;
17:2281–2291.
24.
SorensenAGEmblemKEPolaskovaP, et al.
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.Cancer Res2012;
72:402–407.
25.
TaoXWangLHuiZ, et al.
DCE-MRI perfusion and permeability parameters as predictors of tumor response to CCRT in patients with locally advanced NSCLC.Sci Rep2016;
6:35569.
26.
AliMMJanicBBabajani-FeremiA, et al.
Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma.PLoS One2010;
5:e8727.
27.
DicksonPVHamnerJBSimsTL, et al.
Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.Clin Cancer Res2007;
13:3942–3950.
28.
WinklerFKozinSVTongRT, et al.
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.Cancer Cell2004;
6:553–563.
29.
ZwickSBrixGToftsPS, et al.
Simulation-based comparison of two approaches frequently used for dynamic contrast-enhanced MRI.Eur Radiol2010;
20:432–442.
30.
KohTSBisdasSKohDM, et al.
Fundamentals of tracer kinetics for dynamic contrast-enhanced MRI.J Magn Reson Imaging2011;
34:1262–1276.
31.
AryalMPNagarajaTNKeenanKA, et al.
Dynamic contrast enhanced MRI parameters and tumor cellularity in a rat model of cerebral glioma at 7 T.Magn Reson Med2014;
71:2206–2214.
32.
BisdasSSmrdelUBajrovicFF, et al.
Assessment of progression-free-survival in glioblastomas by intratreatment dynamic contrast-enhanced MRI.Clin Neuroradiol2016;
26:39–45.
33.
UlyteAKatsarosVKLioutaE, et al.
Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients.Neuroradiology2016;
58:1197–1208.
34.
KohTSShiWThngCH, et al.
Interpretation and applicability of empirical tissue enhancement metrics in dynamic contrast-enhanced MRI based on a multiple pathway model.Phys Med Biol2012;
57:N279–N294.
35.
PikeMMStoopsCNLangfordCP, et al.
High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: sequential small molecule and SPIO dynamic contrast agent MRI.Magn Reson Med2009;
61:615–625.
36.
CuiYZhangCLiX, et al.
Intravoxel incoherent motion diffusion-weighted magnetic resonance imaging for monitoring the early response to ZD6474 from nasopharyngeal carcinoma in nude mouse.Sci Rep2015;
5:16389.
37.
ToftsPSWicksDABarkerGJ.The MRI measurement of NMR and physiological parameters in tissue to study disease process.Prog Clin Biol Res1991;
363:313–325.
38.
ChoiYSKimDWLeeSK, et al.
The added prognostic value of preoperative dynamic contrast-enhanced MRI histogram analysis in patients with glioblastoma: analysis of overall and progression-free survival.AJNR Am J Neuroradiol2015;
36:2235–2241.
